Vitura Health (ASX: VIT) is one of the more intriguing ASX cannabis stocks because it combines medical cannabis distribution, patient access services, and digital health solutions rather than being solely a cultivator or manufacturer. The company, formerly known as Cronos Australia, has built an ecosystem that integrates clinics, telehealth, e-commerce platforms and supply chains to boost patient access to regulated medicinal cannabis products.

One of its notable consumer-facing assets is Canview, an online portal that connects patients, prescribers and pharmacists, allowing patients to explore available cannabis medicines and facilitating prescription fulfilment through participating pharmacies. This digital approach aims to streamline and simplify what can be a complex access process under systems like the Therapeutic Goods Administration’s Special Access Scheme (SAS-B) in Australia.

In addition to distribution infrastructure, Vitura operates its own clinics — known as CDA Clinics — and has acquired other telehealth and cannabis consultancy businesses like Candor Medical, strengthening its position as a vertically integrated access provider in the medicinal cannabis market. This model appeals to investors who value recurring revenue streams tied to patient services and platform usage, rather than purely agricultural or commodity-style sales.

LGP is focused on cultivation, production, and distribution of medicinal cannabis products. Unlike specialist biotechs focused solely on drug development, Little Green Pharma operates a vertically integrated model, meaning it grows cannabis, manufactures finished medicinal cannabis medicines, supplies to domestic clinics and pharmacies, and exports into select international markets, particularly Europe.

The company’s strategy also includes strengthening distribution partnerships, expanding product portfolios, and pursuing acquisitions or deals that bolster market reach — moves that may enhance long-term shareholder value if executed successfully. However, as with all cannabis equities, investors should be mindful of regulatory shifts, pricing pressures, and competitive dynamics that can influence earnings prospects.

Cann Group Cann Group is stands as one of the elder statesmen of the Australian medicinal cannabis sector, having been established well ahead of many peers and becoming one of the first ASX-listed companies to receive Australian licences for cultivation, breeding, and manufacturing of medicinal cannabis. Its flagship cultivation facility in Mildura, Victoria supports an end-to-end supply chain from genetics and breeding through to dried flower production and pharmaceutical-grade extraction.

Cann has also developed proprietary product platforms, such as its Satipharm oral delivery technology, which allows consistent dosing of cannabis products — a key consideration in medical applications where precision matters for patient safety and regulatory acceptance. While the company’s share price history has seen volatility, and profitability has fluctuated, Cann’s steady production volume increases and ongoing operational improvements reflect its role as a foundational supplier in the growing Australian medical cannabis market.

Investors often view Cann Group as a core agricultural cannabis investment that is not reliant on a single product or clinical trial outcome. Instead, its value proposition is anchored in scale, cultivation expertise, licensed facilities, and established distribution channels. As demand for regulated medicinal cannabis continues to rise — both domestically and in export markets — Cann’s mature infrastructure and capacity position it to benefit from broader industry growth, while its diversified product portfolio and R&D efforts provide optionality beyond simple flower production.